NCT04077749

Brief Summary

The proposed study is a randomized, placebo-controlled clinical trial to test the efficacy of an oral Lactobacillus product dissolved in sterile saline and instilled into the urinary bladder in an attempt to colonize the urinary bladder as well as prevent UTIs.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Apr 2021

Shorter than P25 for early_phase_1

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 28, 2019

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 4, 2019

Completed
1.6 years until next milestone

Study Start

First participant enrolled

April 1, 2021

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2021

Completed
Last Updated

July 8, 2021

Status Verified

July 1, 2021

Enrollment Period

3 months

First QC Date

August 28, 2019

Last Update Submit

July 2, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Bladder colonization with Lactobacillus

    Percent of patients with urine cultures positive for lactobacilli species after 6 months.

    6 months

Study Arms (2)

Probiotic

EXPERIMENTAL
Biological: Femdophilus probiotic

Placebo

PLACEBO COMPARATOR
Other: Normal Saline

Interventions

Lactobacillus rhamnosus (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of Femdophilus dissolved in 50 mL normal saline at room temperature.

Probiotic

50 mL normal saline at room temperature

Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ≥ 18 years of age
  • Chronic indwelling urethral catheter or supra-pubic tube for \>6 months
  • Prior symptomatic UTI while catheter in place

You may not qualify if:

  • Immunosuppressed (HIV, transplant immunosuppression, uncontrolled diabetes)
  • Active infection (may be considered after treatment of active infection)
  • Prior urosepsis requiring ICU admission
  • Significant gross hematuria resulting from catheter exchanges
  • Supravesical urinary diversion
  • Upper urinary tract anatomical abnormality
  • Obstructing urolithiasis
  • Ongoing antibiotic therapy for non-urological infection
  • Indwelling nephrostomy tube or ureteral stent
  • Radiation cystitis
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Urinary Tract Infections

Interventions

Saline Solution

Condition Hierarchy (Ancestors)

InfectionsUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations
0

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 28, 2019

First Posted

September 4, 2019

Study Start

April 1, 2021

Primary Completion

June 30, 2021

Study Completion

September 15, 2021

Last Updated

July 8, 2021

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will not share